Literature DB >> 1588831

Prolactin responses to phenylalanine and tyrosine in phenylketonuria.

H E Carlson1, D B Hyman, C Bauman, R Koch.   

Abstract

In normal subjects, ingestion of tyrosine or phenylalanine stimulates prolactin (PRL) secretion. In patients with phenylketonuria (PKU), we found normal PRL responses to phenylalanine, demonstrating that conversion of phenylalanine to tyrosine is not necessary for PRL stimulation. PKU patients also showed greater PRL responses to tyrosine during dietary phenylalanine restriction than when consuming an unrestricted diet; this finding is consistent with inhibition by phenylalanine of tyrosine transport across the blood-brain barrier. Such competitive inhibition of a normal brain function may serve as a model for some of the neurotoxic effects of phenylalanine in PKU.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588831     DOI: 10.1016/0026-0495(92)90211-r

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  Phenylalanine and other amino acids in phenylketonuria.

Authors:  P C Clemens; J G Burmester; B H Prankel; G Wiegand; A P Wulke; C Plettner
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

2.  Prolactin, a marker for cerebral dopamine deficiency in patients suffering from phenylketonuria (PKU)?

Authors:  J Denecke; W Schlegel; G H Koch; R Feldmann; E Harms; J Weglage
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

3.  A preliminary report on dopamine system reactivity in PKU: acute effects of haloperidol on neuropsychological, physiological, and neuroendocrine functions.

Authors:  Monica Luciana; Karen L Hanson; Chester B Whitley
Journal:  Psychopharmacology (Berl)       Date:  2004-03-13       Impact factor: 4.530

4.  Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study.

Authors:  Eszter Juhász; Erika Kiss; Erika Simonova; Attila Patócs; Peter Reismann
Journal:  Eur J Med Res       Date:  2016-05-11       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.